2025
Lutris Pharma Secures $30 Million Financing to Advance the Development of Biopharmaceutical to Improve Anti-Cancer Drug Effectiveness
28/01/2025Lutris Pharma, which is invested in Columbus Venture Partners Fund 4, is a clinical stage biopharmaceutical company focused on improving anti-cancer therapy effectiveness and quality of life for patients who are being treated with EGFR (Epidermal Growth Factor Receptor) inhibitors or with radiation, where dermal toxicity often leads to a reduction of anti-cancer therapy compliance.
Read More
Quibim Announces a $50 Million Financing, led by Asabys and Buenavista, to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers
27/01/2025Quibim Announces a $50 Million Financing to Revolutionize Precision Medicine with AI-Powered Imaging Biomarkers. The financing was led by Asabys (through its fund Sabadell Asabys II) and Buenavista Equity Partners through the BHG I fund, created in partnership with Columbus Venture Partners.
Read More
Artax Biopharma achieves clinical validation of first-in-class, oral, Nck modulator AX-158 for autoimmune disease in phase 2a study
23/01/2025Cambridge, MA, January 22, 2025 – Artax Biopharma, Inc., a clinical-stage biotechnology company focused on transforming the treatment of autoimmune diseases, today…
Read More